CoChat
Sign Up
Cited by 508Immune cells in cancerSarcoma Diagnosis and TreatmentCancer Cells and Metastasis

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Buddingh, Emilie P., Kuijjer, Marieke L., Duim, Ronald A.J., Bürger, Horst, Agelopoulos, Konstantin, Myklebost, Ola, Serra, Massimo, Mertens, Fredrik, Hogendoorn, Pancras C.W., Lankester, Arjan C., Cleton-Jansen, Anne-Marie·2011·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-10-2047

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence in adolescence. Overall survival (OS) of patients with resectable metastatic disease is approximately 20%. The exact mechanisms of development of metastases in osteosarcoma remain unclear. Most studies focus on tumor cells, but it is increasingly evident that stroma plays an important role in tumorigenesis and metastasis. We investigated the development of metastasis by studying tumor cells and their stromal context. Experimental Design: To identify gene signatures playing a role in metastasis, we carried out genome-wide gene expression profiling on prechemotherapy biopsies of patients who did (n = 34) and patients who did not (n = 19) develop metastases within 5 years. Immunohistochemistry (IHC) was performed on pretreatment biopsies from 2 additional cohorts (n = 63 and n = 16) and corresponding postchemotherapy resections and metastases. Results: A total of 118/132 differentially expressed genes were upregulated in patients without metastases. Remarkably, almost half of these upregulated genes had immunological functions, particularly related to macrophages. Macrophage-associated genes were expressed by infiltrating cells and not by osteosarcoma cells. Tumor-associated macrophages (TAM) were quantified with IHC and associated with significantly better overall survival (OS) in the additional patient cohorts. Osteosarcoma samples contained both M1- (CD14/HLA-DRα positive) and M2-type TAMs (CD14/CD163 positive and association with angiogenesis). Conclusions: In contrast to most other tumor types, TAMs are associated with reduced metastasis and improved survival in high-grade osteosarcoma. This study provides a biological rationale for the adjuvant treatment of high-grade osteosarcoma patients with macrophage activating agents, such as muramyl tripeptide. Clin Cancer Res; 17(8); 2110–9. ©2011 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2047

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 2

  1. Raymond, 2002, Conventional osteosarcoma, 264
  2. 2005, R: a language and environment for statistical computing, reference index version 2.9.0.

Cited by

Sorted by citations

See all 508

Related

Metadata

Authors
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., & Cleton-Jansen, A.-M.
Affiliations
  • Oslo University Hospital (NO)
  • Authors' Affiliations: 1Department of Pediatrics; 2Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 3Institute of Pathology; 4Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany; 5Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 6Laboratory of Experimental Oncology Research, Istituto Ortopedico Rizzoli, Bologna, Italy; and 7Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
Corresponding author
Cleton-Jansen, Anne-Marie
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2011-04-14
Volume
17
Issue
8
Pages
2110-2119
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-10-2047
OpenAlex
W2106409672
Cited by
508
References
45
Citations by year
2026: 27 · 2025: 45 · 2024: 48 · 2023: 63 · 2022: 47 · 2021: 54 · 2020: 50 · 2019: 24 · 2018: 20 · 2017: 36 · 2016: 24 · 2015: 17 · 2014: 15 · 2013: 13 · 2012: 18
FWCI
7.52
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
high-grade osteosarcoma, tumor-infiltrating macrophages, metastasis suppression, tumor-associated macrophages, tumor stroma, gene expression profiling, overall survival, muramyl tripeptide, adjuvant therapy, CD14, CD163, angiogenesis
MeSH terms
Bone Neoplasms, Humans, Immunohistochemistry, Macrophages, Neoplasm Metastasis, Prognosis, Osteosarcoma, Time Factors, Cohort Studies, Gene Expression Regulation, Neoplastic, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review